Gene Bridges Inks License with Japanese Pharma Firm | GenomeWeb

NEW YORK (GenomeWeb News) – German genetic engineering company Gene Bridges said today that it has licensed its DNA recombination technology to Japanese pharmaceutical firm Daiichi Sankyo.

The company said that the technology, which is patented in Japan as a "Novel DNA Cloning Method," is used to generate targeting vectors or for modifying E. coli chromosomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.